Growth of a fifth for Sandoz’ Biopharmaceuticals business – driven by the continued success of its biosimilars portfolio, in Europe and elsewhere – has offset the negative impact of COVID-19 on the company’s retail generics business in 2020, allowing the Novartis off-patent unit to report sales that were steady compared to the previous year.
Biosimilars Boost Offsets Generics Slide For Sandoz
Sales Remain Steady In 2020 Despite Turbulence Of COVID-19
Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.
More from Earnings
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.
• By
Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.